Evaluation of inhibitory action of novel non b-lactam inhibitor against klebsiella pneumoniae carbapenemase (KPC-2)

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Khan, Arbab ^a   Faheem, Mohammad ^a   Danishuddin, Mohd ^a   Khan, Asad U ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEMASE; CARBAPENEMASE KPC 2; CLAVULANIC ACID; ERTAPENEM; IMIPENEM; MEROPENEM; SULBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG; ZINC 01807204; ZINC 02318494; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE KPC-2, KLEBSIELLA PNEUMONIAE; CARBAPENEM DERIVATIVE; PROTEIN BINDING; THIENAMYCIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; HELA CELL LINE; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

KLEBSIELLA PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CELL LINE; HELA CELLS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; THIENAMYCINS;

EID: 84907486093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108246     Document Type: Article

References (18)

1. Bush K, Jacoby GA. (2010). Updated functional classification of beta-lactamases. Antimicrob. Agents Chemother. 54: 969-976
2. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, et al (2001). Novel carbapenem-hydrolyzing b-lactamase, KPC-1, from a carbapenem- resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45: 1151-1161
3. Walther-Rasmussen J, Hoiby N (2007). Class A carbapenemases. J. Antimicrob. Chemother. 60: 470-482
4. Yigit H, Queenan AM, Rasheed JK, Biddle JW, Domenech-Sanchez A, et al (2003). Carabapenem-resistant strain of Klebsiella oxytoca harbouring carbapenem- hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother. 47: 3881-3889
5. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, et al (2010). Inhibitor resistance in KPC-2 b-lactamase, a pre-eminent property of this class A b-lactamase. Antimicrob Agents Chemother. 54(2): 890-897
6. Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F (2007). Crystal structure of KPC-2: Insights into carbapenemase activity in class A b-lactamases. Biochemistry. 46: 5732-5740
7. Queenan AM, Foleno B, Gownley C, Wira E, Bush K (2004). Effects of inoculum and b-lactamase activity in AmpC- and extended-spectrum blactamase (ESBL)-producing Escherichia coli and Klebsiella pneumonia clinical isolates tested by using NCCLS ESBL methodology. J. Clin. Microbiol. 42: 269-275
8. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, et al (2005). Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49: 3018-3020
9. Bebrone C, Lassaux P, Vercheval L, Sohier JS, Jehaes A, et al (2010). Current challenges in antimicrobial chemotherapy-focus on b-lactamase inhibition. Drugs. 70 (6): 651-679
10. Danishuddin M, Khan A, Faheem M, Kalaiarasan P, Baig MH, et al (2013). Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug resistant bacteria. J Biomol Struct Dyn. 32(5): 741-50
11. Papp-wallace KM, Taracila MA, Smith KM, Xu Y, Bonomo RA (2012). Understanding the molecular determinants of substrate and inhibitor specificities in the carbapenemase KPC-2: Exploring the roles of Arg220 and Glu276. Agents Antimicrob Chemother. 56(8): 4428-4438
12. Clinical and Laboratory Standards Institute (2014). Performance standards for antimicrobial susceptibility testing: 24 informational supplement. M100-S24, CLSI, Wayne, PA.
13. Hasan S, Danishuddin M, Adil M, Singh K, Verma PK, et al (2012). Efficacy of E. officinalis on the cariogenic properties of Streptococcus mutans: A novel and alternative approach to suppress quorum sensing mechanism. Plos One. 7(7): E40319. doi: 10.1371/journal.pone.0040319
14. Jafarian A, Zolfaghari B and Shirani K (2014). Cytotoxicity of different extracts of arial parts of Ziziphus spina-christi on HeLa and MDA-MB-468 tumor cells. Adv Biomed Res. 3: 38
15. Faheem M, Rehman MT, Danishuddin M, Khan AU (2013). Biochemical characterization of CTXM-15 from Enterobacter cloacae and designing a novel non-b-lactam b-lactamases inhibitor. PLoS ONE. 8(2): E56926. doi:10.1371/ journal.pone.0056926
16. Hanes MS, Jude KM, Berger JM, Bonomo RA, Handel TM (2009). Structural and biochemical characterization of the interaction between KPC-2 b-lactamase and b-lactamase inhibitor. Biochemistry. 48: 9185-9193
17. Cheng YC, Prusoff WH (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 22: 3099-3108
18. Frere JM, Dormans C, Lenzini VM, Duyckaerts C (1982). Interaction of clavulanate with the b-lactamases of Streptomyces albus G and Actinomadura R39. Biochem. J. 207: 429-436